Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: povidone; hypromellose; alginic acid; citric acid monohydrate; microcrystalline cellulose; magnesium stearate; purified talc; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: povidone; alginic acid; citric acid monohydrate; magnesium stearate; hypromellose; purified talc; microcrystalline cellulose; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: alginic acid; povidone; microcrystalline cellulose; citric acid monohydrate; magnesium stearate; purified talc; hypromellose; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide yellow; propylene glycol; povidone; sodium lauryl sulfate; magnesium stearate; titanium dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); mannitol; light magnesium oxide; purified talc; hyprolose; polysorbate 80; ethylcellulose - rabeprazole is indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fentanyl, quantity: 16.5 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fentanyl, quantity: 12.375 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fentanyl -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fentanyl -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sildenafil citrate -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sildenafil citrate -